• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Waters Corporation

    6/13/25 4:15:59 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email
    S-8 1 d20731ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 13, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    WATERS CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   13-3668640

    (State or other jurisdiction of

    incorporation) or organization)

     

    (I.R.S. Employer

    Identification No.)

    34 Maple Street

    Milford, Massachusetts 01757

    (Address of Principal Executive Offices) (Zip Code)

     

     

    Waters Corporation

    Amended and Restated 2009 Employee Stock Purchase Plan

    (Full title of the plan)

     

     

    Keeley A. Aleman, Esq.

    Waters Corporation

    34 Maple Street

    Milford, Massachusetts 01757

    (Name and address of agent for service)

    508-478-2000

    (Telephone number, including area code, for agent for service)

     

     

    Copies to:

    Jennifer L. Lee, P.C.

    Zoey Hitzert

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    (212) 446-4800

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer    ☒     Accelerated filer    ☐ 
    Non-accelerated filer    ☐     Smaller reporting company    ☐ 
         Emerging growth company    ☐ 

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ 

     

     
     


    EXPLANATORY NOTE

    Waters Corporation (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) solely to register 750,000 additional shares of its common stock, $0.01 par value per share (the “Common Stock”) that may be offered or sold pursuant to the Waters Corporation Amended and Restated 2009 Employee Stock Purchase Plan (the “Plan”), which were added to the Plan when an amendment and restatement of the Plan was approved by a vote of the Registrant’s stockholders on May 22, 2025.

    The Registrant previously registered shares of its Common Stock under the Plan pursuant to a Registration Statement on Form S-8 (File No. 333-160507) filed on July 10, 2009 (the “2009 Registration Statement”). Pursuant to General Instruction E to Form S-8, the contents of the 2009 Registration Statement are incorporated into this Registration Statement by reference, except that the provisions contained in Part II of the 2009 Registration Statement are modified as set forth below.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference into this Registration Statement:

    (a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February  25, 2025;

    (b) the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 6, 2025;

    (c) the Registrant’s Current Reports on Form 8-K, filed with the Commission on May 23, 2025 and May 29, 2025;

    (d) the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April  9, 2025; and

    (e) the description of the Registrant’s Common Stock, which is contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K filed with the Commission on February 24, 2021, including any amendment or report filed for the purpose of updating such description.

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents with the Commission.

    Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such prior statement. Any statement contained in this Registration Statement shall be deemed to be modified or superseded to the extent that a statement contained in a subsequently filed document that is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information furnished under Items 2.02 or 7.01 of Current Report on Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.


    Item 6. Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) permits a corporation to indemnify any person who is or has been a director, officer, employee or agent of the corporation or who is or has been serving as director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise at the request of the corporation, against expenses (including, but not limited to, attorneys’ fees and disbursements and amounts paid in settlement or in satisfaction of judgments or as fines or penalties) actually and reasonably incurred in connection with any action, suit or proceeding, whether civil, criminal, administrative or investigative, in which he/she may be involved by reason of the fact that he/she served or is serving in these capacities, if he/she acted in good faith and in a manner he/she reasonably believed to be in or not opposed to the best interest of the corporation and, with respect to any criminal action or proceeding, had no cause to believe his/her conduct was unlawful. In the case of an action, suit or proceeding made or brought by or in the right of the corporation to procure a judgment in its favor, the corporation shall not indemnify such person in respect of any claim, issue or matter as to which such person has been adjudged to be liable to the corporation, except for such expenses as the court may allow. Any such person who has been wholly successful on the merits or otherwise with respect to any such action, suit or proceeding or with respect to any such claim, issue or matter therein, shall be indemnified against all expenses actually and reasonably incurred in connection therewith. The Registrant’s certificate of incorporation, as amended, provides for the indemnification of directors and officers of the Registrant to the fullest extent permitted by Section 145.

    In addition, Section 102(b)(7) of the DGCL provides that a corporation may eliminate or limit the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable, provided that such provision shall not eliminate or limit the liability of a director or officer, as applicable, (i) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director or officer derived an improper personal benefit. No such provision shall eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision becomes effective. The Registrant’s amended and restated certificate of incorporation limits the liability of its directors and officers to the fullest extent permitted by the DGCL, as such may be amended. No amendment to or repeal of this provision of the Registrant’s amended and restated certificate of incorporation will apply to, or have any effect on, the liability or alleged liability of any director or officer for, or with respect to, any acts or omissions of such director or officer occurring prior to such amendment or repeal.

    The amended and restated bylaws of the Registrant provide that to the fullest extent permitted by the DGCL, as such may be amended, that a director of the Registrant shall not be liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director.

    In addition, pursuant to certain indemnification agreements between the Registrant and its directors and executive officers, the Registrant has agreed to indemnify such directors and executive officers to the fullest extent permitted by Delaware law. Among other things, the indemnification agreements provide indemnification procedures, advancement of expenses during proceedings subject to indemnification and mechanisms for reviewing executive conduct in connection with a claim for indemnification.


    Item 8. Exhibits.

     

    Exhibit No.

      

    Description

     4.1

       Waters Corporation Amended and Restated 2009 Employee Stock Purchase Plan

     5.1

       Opinion of Kirkland & Ellis LLP

    23.1

       Consent of PricewaterhouseCoopers LLP

    23.2

       Consent of Kirkland & Ellis LLP (included as part of Exhibit 5.1)

    24.1

       Power of Attorney (included on signature page)

    107

       Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Milford, Massachusetts, on this 13th day of June, 2025.

     

    WATERS CORPORATION

    By:   /s/ Amol Chaubal
    Name:   Amol Chaubal
    Title:   Senior Vice President and Chief Financial Officer

    POWER OF ATTORNEY

    We, the undersigned officers and directors of the Registrant, hereby severally constitute and appoint Udit Batra, Amol Chaubal, and Keeley A. Aleman, or any of them, with full power of substitution and re-substitution and full power to act without the other, as our true and lawful attorneys-in-fact and agents, for such persons and in such persons’ name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such persons might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated as of the 13th day of June, 2025.

     

    Signature

      

    Title

    /s/ Dr. Flemming Ornskov, M.D., M.P.H.

    Dr. Flemming Ornskov, M.D., M.P.H.

       Chair of the Board of Directors

    /s/ Udit Batra, Ph.D.

       President and Chief Executive Officer; Director
    Udit Batra, Ph.D.    (Principal Executive Officer)

    /s/ Amol Chaubal

       Senior Vice President and Chief Financial Officer
    Amol Chaubal    (Principal Financial Officer)
    (Principal Accounting Officer)

    /s/ Linda Baddour

       Director
    Linda Baddour   

    /s/ Dan Brennan

       Director
    Dan Brennan   

    /s/ Richard Fearon

       Director
    Richard Fearon   

    /s/ Pearl S. Huang, Ph.D.

       Director
    Pearl S. Huang, Ph.D.   

    /s/ Wei Jiang

       Director
    Wei Jiang   

    /s/ Heather Knight

      

    Director

    Heather Knight   

    /s/ Christopher A. Kuebler

       Director
    Christopher A. Kuebler   

    /s/ Mark Vergnano

       Director
    Mark Vergnano   
    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    12/2/2025$423.00Equal-Weight
    Morgan Stanley
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kuebler Christopher A exercised 3,761 shares at a strike of $130.35 and covered exercise/tax liability with 1,318 shares, increasing direct ownership by 16% to 17,478 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    11/7/25 7:00:43 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Knight Heather was granted 78 shares, increasing direct ownership by 11% to 759 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:16:38 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Jiang Wei was granted 73 shares, increasing direct ownership by 3% to 2,551 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:15:15 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Corporation to Present at the Jefferies Global Healthcare Conference in London

    MILFORD, Mass., Nov. 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, 2025, at 2:30 PM Greenwich Mean Time (9:30 AM Eastern Time). A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, m

    11/11/25 2:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software

    Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS).Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1Delivers near-universal detection of an expansive range of analytes across pharmaceutical formulations, food additives, and environmental pollutants, including those that are challenging to measure using UV or mass spectrometry methods.MILFORD, Mass., Nov. 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software,

    11/11/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    SEC Filings

    View All

    SEC Form S-4 filed by Waters Corporation

    S-4 - WATERS CORP /DE/ (0001000697) (Filer)

    12/11/25 9:13:50 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    11/18/25 4:28:10 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    11/10/25 4:16:47 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Waters upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Waters from Peer Perform to Outperform and set a new price target of $480.00

    12/10/25 8:13:37 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Morgan Stanley initiated coverage on Waters with a new price target

    Morgan Stanley initiated coverage of Waters with a rating of Equal-Weight and set a new price target of $423.00

    12/2/25 8:36:30 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Waters with a new price target

    Rothschild & Co Redburn initiated coverage of Waters with a rating of Buy and set a new price target of $390.00

    10/8/25 8:37:34 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Richard Fearon to Board of Directors

    Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

    3/28/23 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety

    10/1/25 12:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results

    Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currencyGAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customersRecurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growthIn constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expectedRaising full-year 2025 constant currency sales growth guidance to +5.5% to

    8/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials